Meeting
2023 ASCO Annual Meeting
A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations.
Authors
J. Thaddeus Thaddeus Beck
Highlands Oncology Group, Springdale, AR
J. Thaddeus Thaddeus Beck , Meredith McKean , Shirish M. Gadgeel , Daniel W. Bowles , Rizwan Haq , Rona Yaeger , Matthew H. Taylor , Arnab K. Maity , Stefanie Drescher , Colleen Oliver , Ann Marie Huelskamp , Gang Feng , Keren Sturtz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT05355701
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3164)
DOI
10.1200/JCO.2023.41.16_suppl.TPS3164
Abstract #
TPS3164
Poster Bd #
356b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.
First Author: Alexander E. Drilon
Poster
2019 ASCO Annual Meeting
A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors.
First Author: Gary Edward Richardson
Poster
2017 ASCO Annual Meeting
Phase I study to evaluate the tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of PM01183 (Lurbinectedin) in combination with olaparib in patients with advanced solid tumors.
First Author: Andres Poveda
Poster
2017 ASCO Annual Meeting
A phase I study of the tolerability, safety, pharmacokinetics and preliminary antitumor effects of KBP-5209, a novel pan-HER inhibitor, in patients with advanced solid tumors.
First Author: Sarina Anne Piha-Paul